US equities |
MU $953.19 ▲+0.00% SNDK $1,482.33 ▲+0.00% ASML $1,717.76 ▲+0.00% SKHY $157.06 ▲+0.00% INTC $102.81 ▲+0.00% NVDA $228.52 ▲+0.00% SPCX $156.54 ▲+0.00% AMD $605.53 ▲+0.00%
FinancialContent

Kiniksa Pharmaceuticals International, plc - Class A Ordinary Shares (NQ:KNSA)

78.53 UNCHANGED
Delayed Quote Updated: 4:00 PM EDT, Oct 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Kiniksa Pharmaceuticals International, plc - Class A Ordinary Shares

< Previous 1 2 3 4 5 6 Next >
Kiniksa Pharmaceuticals (NASDAQ:KNSA) Pairs Strong Growth With a High-Quality Technical Setup ↗
Via Chartmill
Kiniksa Pharmaceuticals (NASDAQ:KNSA): Affordable Growth Backed by Accelerating Earnings ↗
Via Chartmill
Kiniksa Pharmaceuticals (NASDAQ:KNSA) Pairs High Growth Momentum With a Breakout Setup ↗
Via Chartmill
Kiniksa Pharmaceuticals (NASDAQ:KNSA) Meets Minervini Trend Template and High-Growth Momentum Criteria ↗
Via Chartmill
Kiniksa Pharmaceuticals (NASDAQ:KNSA) Combines Strong Growth With a High-Quality Technical Setup ↗
Via Chartmill
Kiniksa Pharmaceuticals (NASDAQ:KNSA) Combines High Growth Momentum with a Breakout Setup ↗
Via Chartmill
Kiniksa Pharmaceuticals (NASDAQ:KNSA) Shows Strong Growth and a Technical Setup for a Potential Breakout ↗
Via Chartmill
Kiniksa Pharmaceuticals (NASDAQ:KNSA): A Compelling Affordable Growth Story ↗
Via Chartmill
News headline image
Kiniksa Highlights ARCALYST Growth as KPL-387 Advances Into Phase 3 ↗
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) said its commercialized recurrent pericarditis treatment ARCALYST continues to grow, while the company has begun a pivotal Phase 3 study of follow-on... 
Via MarketBeat
Kiniksa Pharmaceuticals (NASDAQ:KNSA) Growth Stock Surges on Revenue Beat and Raised Guidance ↗
Via Chartmill
Kiniksa Pharmaceuticals (NASDAQ:KNSA): A High-Growth Stock with Strong Technical Setup ↗
Via Chartmill
Kiniksa Pharmaceuticals (NASDAQ:KNSA): A High Growth Momentum Stock With a Breakout Setup ↗
Via Chartmill
Which stocks are gapping on Tuesday? ↗
Via Chartmill
News headline image
Kiniksa Pharmaceuticals International Q2 Earnings Call Highlights ↗
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) reported second-quarter ARCALYST revenue of $243.6 million, up 55% from a year earlier and more than $29 million from the first quarter, as the... 
Via MarketBeat
Topics Artificial Intelligence Earnings
Kiniksa Pharmaceuticals (NASDAQ:KNSA) Qualifies as an Affordable Growth Stock With Strong Revenue and Earnings Momentum ↗
Via Chartmill
Kiniksa Pharmaceuticals International Plc (NASDAQ:KNSA) Presents a Compelling GARP Opportunity ↗
Via Chartmill
News headline image
Kiniksa (KNSA) Q1 2026 Earnings Transcript ↗
Kiniksa (KNSA) Q1 2026 Earnings Transcript 
Via The Motley Fool
Topics Artificial Intelligence
Kiniksa Pharmaceuticals (NASDAQ:KNSA) Screens as Affordable Growth ↗
Via Chartmill
Kiniksa Pharmaceuticals (KNSA) Shows Explosive Potential with Perfect Minervini Trend Template and 460% EPS Growth ↗
Via Chartmill
News headline image
Kiniksa Pharmaceuticals Still Has Room to Run After 100% Rally ↗
Kiniksa Pharmaceuticals is gaining momentum after strong ARCALYST sales growth, raised revenue guidance, and optimism surrounding its next-generation pipeline 
Via MarketBeat
News headline image
Why Kiniksa Pharmaceuticals International Stock Raced Nearly 24% Higher Today ↗
The biotech delivered a beat-and-raise first quarter. 
Via The Motley Fool
Gapping stocks in Tuesday's session ↗
Via Chartmill
Kiniksa Pharmaceuticals (NASDAQ:KNSA) Surges on Q1 Earnings Beat and Raised ARCALYST Guidance ↗
Via Chartmill
Topics Earnings
Kiniksa Pharmaceuticals (NASDAQ:KNSA) Surfaces as a GARP Opportunity with a Growth Rating of 8 ↗
Via Chartmill
Kiniksa Pharmaceuticals (NASDAQ:KNSA) Fits the Minervini Trend Template with High-Growth Momentum ↗
Via Chartmill
Kiniksa Pharmaceuticals (NASDAQ:KNSA) Presents a Compelling Growth and Technical Setup ↗
Via Chartmill
Kiniksa Pharmaceuticals (NASDAQ:KNSA) Presents a High-Growth Momentum Setup ↗
Via Chartmill
Kiniksa Pharmaceuticals (NASDAQ:KNSA) Emerges as a Top GARP Investment ↗
Via Chartmill
News headline image
What This $309K Kiniksa Insider Sale Might Signal Amid a 120% Stock Surge ↗
This biotech innovator in inflammatory disease therapies reported a notable insider sale amid strong revenue growth and recent stock gains. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Kiniksa Pharmaceuticals (KNSA) Shows High Growth Momentum and Technical Breakout Potential ↗
Kiniksa Pharmaceuticals (KNSA) exemplifies a high-growth momentum stock with strong fundamentals and a positive technical setup for potential breakout. 
Via Chartmill
< Previous 1 2 3 4 5 6 Next >